Lupin launches generic Femhrt tablets in US

Drug firm Lupin has launched its generic norethindrone acetate and ethinyl estradiol tablets, used for the prevention of postmenopausal osteoporosis, in the US market.

The company's US subsidiary, Lupin Pharmaceuticals Inc, has launched FyavolvTM tablets (Norethindrone Acetate and Ethinyl Estradiol tablets USP, 0.5 mg/0.0025 mg and 1 mg/0.005 mg), in the American market, Lupin said in a BSE filing.

The company had earlier received an approval from the United States Food and Drug Administration to market the product, it added.

Read more from our special coverage on "LUPIN"

• Lupin gains on launch of first product from GAVIS pipeline in the US
• Lupin launches generic insomnia drug in US
• Stocks drop for second day as Lupin falls most since 08
• Lupin gets three observations from USFDA for Mandideep plant
• Nifty Pharma index hits 52-week low; Lupin at 18-month low

The product is generic version of Warner Chilcott's Femhrt tablets in the same strengths, Lupin said.

Femhrt had US sales of $39 million (IMS MAT December 2015), it added.

The tablets are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis, Lupin said.

Stock of Lupin closed 1.65% higher at Rs 1,569.30 on BSE.